Hyperfly Feature: AI and Analytics for Smarter HCP Engagement
AIHCP InsightsABIESelection Intelligence
The decision of which HCP to engage for which activity is one of the most consequential and most data-intensive choices in pharma operations. Too often it is made on the basis of familiarity — the experts your team already knows, the faces they have seen at recent congresses. Hyperfly’s AI capabilities change this: surfacing 20+ real-time data signals at the point of selection, generating AI-powered HCP intelligence summaries, and providing the ABIE toolkit to extract strategic value from advisory board engagement data.
Hyperfly AI and Analytics Capabilities
- 20+ real-time HCP selection signals — compliance, suitability, and strategic fit data at the point of shortlisting
- HCP Insights (AI-generated) — synthesised summaries of all field intelligence about each HCP
- ABIE (Advisory Board Interrogation Engine) — AI toolkit for extracting strategic insights from advisory board outputs
- Shortlist Probability Scoring — quantitative estimate of HCP acceptance and participation probability
- DNA History Analysis — predictive modelling based on HCP’s historical engagement acceptance and attendance patterns
- Utilisation Intelligence — identifying over-reliance on specific HCPs and surfacing underutilised alternatives
The 20+ HCP Selection Intelligence Signals
At the moment of shortlisting any HCP for an engagement, Hyperfly presents a comprehensive real-time intelligence view covering every factor that should inform the selection decision:
| Signal | What It Shows |
|---|---|
| CAPS Limitations | Whether participation will breach time, activity, or monetary caps in the current reporting cycle |
| DNE Flags | Public debarment, OIG exclusion, or private internal holds — including event-type-specific restrictions |
| Utilisation Level | Whether the HCP is over-utilised relative to peers, with suggested alternatives to improve portfolio diversity |
| Advocacy Objectives | Alignment between event objectives and HCP-specific advocacy pathway goals |
| HCP Self-Reported Preferences | Languages, geographies, and activity types the HCP has confirmed they will or will not do |
| HCP Unavailability | Known unavailability during the planned period based on HCP-submitted information or internal intelligence |
| Internal Event Conflict | Whether the HCP is already scheduled for another of your events in close proximity |
| External Event Conflict | Whether a major public event (e.g., a key congress) overlaps with the planned engagement |
| DNA History | Historical Did Not Accept and Did Not Attend rates — predictive of future acceptance probability |
| Engagement Plan Status | Whether the HCP is part of active or provisional engagement plans that conflict with this activity |
| Contracting Status | Whether a current MSA or contract will cover the proposed engagement period |
| Budget Fit | Whether engaging this HCP aligns with the approved budget for the engagement |
| Consent Status | Whether data privacy and ToV reporting consent are active and valid |
| Shortlist Probability Score | AI-generated quantitative estimate of acceptance and successful participation probability |
| HCP Insights (AI) | AI-generated summary of all field intelligence from prior MSL and medical affairs interactions |
| Affiliate Requirements | Country-level approval requirements for top-tier local KOLs |
| Global HQ Requirements | HQ-level approval requirements for globally significant KOLs |
| BYE Notes | Before You Engage advisories generated manually or automatically from all prior history |
ABIE: Advisory Board Interrogation Engine
ABIE is Hyperfly’s AI toolkit for advisory board intelligence — designed to help pharma teams extract maximum strategic value from the scientific outputs of their advisory board programmes. Rather than leaving advisory board insights in meeting notes and summary documents, ABIE enables teams to interrogate advisory board data, identify patterns across multiple advisory sessions, and generate synthesised strategic outputs from engagement content.
Frequently Asked Questions
Does Hyperfly’s AI replace human judgement in HCP selection?
No. Hyperfly’s AI selection intelligence is designed to inform and enhance human decision-making — not replace it. The platform surfaces all relevant data signals at the point of selection, surfaces risks and conflicts the team might not have considered, and generates a probability score as an analytical input. The final selection decision remains with the human team. AI ensures that decision is made with complete information rather than partial knowledge.
Where does the data for HCP Insights come from?
HCP Insights AI summaries are generated from intelligence gathered by field medicine teams, MSLs, and other functions from all prior interactions with each HCP — including interaction notes captured in the platform, field intelligence submitted through integrated CRM systems like Veeva, and any other structured intelligence inputs configured for your programme. The AI synthesises this data into a concise, up-to-date summary presented at the point of shortlisting.
Make Smarter HCP Selection Decisions With Real-Time AI Intelligence
→ Request a Hyperfly demo — see HCP Insights and ABIE in action
Works best when combined with:
- Compliance and Risk Management — AI selection signals include compliance data (DNE, CAPS, FMV proximity)
- Workflow Automation — AI intelligence powers the Shortlist workflow module
- Reporting and Transparency — analytics outputs feed into performance reporting